Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2019

View Archived Issues

Scientists report new telomerase partner protein

Glutamate receptor predicts suicidality in PTSD

Injection of CSF from multiple sclerosis patients generates mouse model of cerebellar dysfunction

New ICOS agonist improves immune checkpoint inhibition in cancer models

SBIR grant supports Western Oncolytics' development of WO-VET-S3

Phase III ClarIDHy study of Tibsovo in cholangiocarcinoma meets primary endpoint

Compass opens first-in-human study of CTX-471 in malignancies that progress on PD-1/PD-L1 inhibitors

Oral antisense-miRNA-214 as a possible treatment for colitis

New phase II HopES study to investigate SM-88 in high-risk sarcomas

Argenx expands pipeline with ARGX-117 and ARGX-118

APRINOIA Therapeutics awarded Michael J. Fox Foundation grant for Parkinson's research

Quinolinone SRI-34329 inhibits Venezuelan equine encephalitis virus at micromolar concentrations

Modulation of PIK3C2B improves vaccination against influenza in PHIV children

FDA lifts target class clinical hold for lanifibranor

Softer touch enhances drug delivery efficiency

GSK-2831781 begins phase II trial in moderate to severe active ulcerative colitis

ChemoCentryx divulges C5AR1 antagonists

Amgen discloses APLNR agonists

Norovirus VLP vaccine TAK-214 immunogenic, well tolerated in phase II study

GlaxoSmithKline identifies IDO1 inhibitors

U.S. researchers present ALDH1A1 inhibitors

FDA grants marketing authorization to Zika virus diagnostic test

Bioimics identifies bacterial ribonuclease P inhibitors

Synlogic enters collaboration with Roche to study SYNB-1891 with Tecentriq in advanced tumors

SBIR grant supports Sentia's development of astressins for IBS

NIAID begins phase I/II study of RSV vaccines in children aged 6-24 months

Cyxone to seek clearance for phase I study of MS drug candidate T20K

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...